Global Pigmented Villonodular Synovitis Drug Market Overview:
Pigmented villonodular synovitis (PVNS) is a disorder that causes the synovium that is the thin layer of tissue that lines the joints and tendons so as to thicken and overgrow. The mass or tumor which hence results from this overgrowth is not at all cancerous and even does not spread to the other areas of the body. PVNS is a highly progressive disease, however, which slowly worsens with time and can further lead to bone damage and in turn arthritis. PVNS generally affects the knee area although it can also affect the other joints as well. In most cases, surgery is mostly needed so as to remove the impaired joint lining and all the mass. The synovium produces a very small amount of fluid that helps in lubricating the cartilage and further aids in the movement. But during PVNS, the synovium produces some extra fluids, hence causing swelling in the joint and therefore making the movement very painful. In around 80 percent of the patients, the knee is highly involved, but at the same time, PVNS can also affect the other parts such as the shoulder, hip, ankle, and elbow. This condition can affect people of all ages, but it usually occurs most often in young adults during their 30s and 40s. The doctor performs a physical examination and uses imaging studies and some other tests for diagnosing PVNS such as X-rays, MRI, joint aspiration, and biopsy. The pigmented villonodular synovitis is at first treated with the help of surgery so as to remove the maximum of the abnormal tissue growth that is possible. This type of surgery particularly depends upon the location and the extent of the disease within the joints. Furthermore, radiation therapy is also sometimes used for the treatment of this condition if at all surgery is not an option, or if the condition again returns after the initial surgery. A drug named Pexidartinib was permitted for the treatment of the patients having the symptomatic tenosynovial giant cell tumor (TGCT) that is also associated with the severe illness or the functional limitations and are not amenable towards improvement with the surgery.
Market Drivers
- Increasing Number of Pigmented Villonodular Synovitis Patients Worldwide
- The Rising Usage because of its Cost-Effectiveness
- Growing Geriatric Population in Major Economies
Market Trend
- Increasing Healthcare Spending and Demand for Drug Therapy
Restraints
- Stringent Government Rules and Regulation
- Side Effects Due to Pigmented Villonodular Synovitis Drug
Opportunities
- Research & Development and Product Innovation
- Potential Growth From Emerging Countries
Challenges
- Unawareness About the Disease and Treatment in the Developing Regions
Competitive Landscape:
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Bristol-Myers Squibb Co (United States), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Plexxikon Inc (United States) and Daiichi Sankyo, Inc (Japan). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Pigmented Villonodular Synovitis Drug market by 2025. Considering Market by Distribution Channel, the sub-segment i.e. Online will boost the Pigmented Villonodular Synovitis Drug market. Considering Market by Form, the sub-segment i.e. Tablet will boost the Pigmented Villonodular Synovitis Drug market. Considering Market by End-User, the sub-segment i.e. Hospital Pharmacy will boost the Pigmented Villonodular Synovitis Drug market.
Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Pigmented Villonodular Synovitis Drug market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Pigmented Villonodular Synovitis Drug market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Pigmented Villonodular Synovitis Drug, Suppliers and Distributors of Pigmented Villonodular Synovitis Drug, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.